Fenofibrate-induced massive regression of mutiple inflammatory hepatocellular adenoma - 01/02/16
Doi : 10.1016/j.clinre.2015.09.009
Raoul Poupon a, ⁎ 
, Dominique Cazals-Hatem b, Lionel Arrivé c
, Dominique Cazals-Hatem b, Lionel Arrivé c a Service d’hépatologie, hôpital Saint-Antoine, AP–HP, Paris, France
b Service d’anatomie et cytologie pathologiques, hôpital Beaujon, AP–HP, Paris, France
c Service de radiologie, hôpital Saint-Antoine, AP–HP, Paris, France
⁎Corresponding author.
Summary |
Inflammatory hepatocellular adenomas (IHCA), which accounts for 40% to 50% of all hepatocellular adenomas are characterized by the activation of the IL6/JAK/STAT pathway. We herein report the case of a 52-year-old woman presenting with severe multiple typical IHCA that regressed dramatically on treatment with fenofibrate, a PPAR agonist known to prevent IL6-induced inflammation experimentally and in humans. Further similar observations are needed to ascertain the potential benefit of this therapeutic approach for large or unresectable IHCA.
El texto completo de este artículo está disponible en PDF.Esquema
© 2015
Elsevier Masson SAS. Reservados todos los derechos.
Vol 40 - N° 1
P. e1-e3 - février 2016 Regresar al número
Artículo precedente
- Different bismuth-based therapies for eradicating Helicobacter pylori: Randomized clinical trial of efficacy and safety
- Hale Gokcan, Erkin Oztas, Ibrahim Koral Onal
- Ménétrier's disease: Long-term remission with lanreotide
- Alexandra Heurgué-Berlot, Thomas Féron, Jean-François Jazeron, Christine Hoeffel, Marie-Danièle Diebold, Guillaume Cadiot
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?